$LAB News

Standard BioTools Inc (NASDAQ:LAB) Shares Rise After Q1 Earnings Beat

Standard BioTools Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $81.504M Est

Standard BioTools Q1 EPS $(0.04) Beats $(0.06) Estimate, Sales $21.146M Beat $17.914M Estimate

Standard BioTools (LAB) is One of the Best Life Sciences Penny Stocks, Here is Why

Labrador Gold Welcomes Recent Announcement by the Ontario Government Concerning Accelerated Development of the Ring of Fire Road

Labrador Gold Announces Closing of Change of Business and Acquisition of Units of Northern Shield

CORRECTION – Labrador Gold Announces Voting Results of the 2026 Annual General and Special Meeting of Shareholders

Labrador Gold Announces Voting Results of the 2026

Labrador Gold Announces Voting Results of the 2026 Annual General and Special Meeting of Shareholders

Standard BioTools Inc (NASDAQ:LAB) Surges on Strong Q4 Earnings Beat

Standard BioTools: Q4 Earnings Snapshot

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

Standard BioTools shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates.

Standard BioTools shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates.

Standard BioTools Q4 Earnings Report: What Investors Need to Know

Standard BioTools Sees FY2026 Sales $80.000M-$85.000M vs $79.727M Est

Standard BioTools Q4 EPS $0.05 Beats $(0.06) Estimate, Sales $23.795M Beat $18.502M Estimate

Preview: Standard BioTools's Earnings

Standard BioTools (NASDAQ:LAB) shareholders have endured a 76% loss from investing in the stock five years ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue